Read the latest news and explore the latest media coverage about Jeeva
“Information technology, underpinned by advancements in Cloud computing, is no longer the understudy to the scientific, R&D lead. Biotech, pharma, healthcare and medtech organizations need to understand that building a fully integrated, enterprise level digital ecosystem is no longer a buzzword or passing trend. ”
Both sides need options. Clinical trial participants need to be able to get information from the comfort and safety of their own homes. Trial sponsors need to make the field of participants as diverse as possible, and at the same time, they need to make sure they’re getting informed consent. Digital technology—particularly Bring Your Own Device (BYOD)—is the way to satisfy all stakeholder requirements.
“ Today, U.S. Senator Tim Kaine is highlighting small business success stories from across the Commonwealth in honor of National Small Business Week (May 1-7), a week dedicated to supporting small businesses. As the Senate debates additional legislation to support small businesses, Kaine will continue to make the case about why more support for Virginia small businesses is necessary.”
“As new non-COVID-related clinical trials proliferate, the need for effective global decentralized CT management is becoming even more apparent. What is needed, says Dr. Harsha Rajasimha of Jeeva Informatics, is to expand the capabilities of validated and human-centric digital technology.”
“Continuity and integrity became a challenge during the last couple of years, and the overall challenge remains the same: recruitment and keeping patients for the duration of the trial so we have complete and accurate evidence about its safety and efficacy.”
“Every country needs a national organization advocating for patients with rare disorders. We saw enormous progress in the US in the last 38 years after Orphan Drugs regulations were adopted. IndoUSrare is connecting resources and expertise across international borders by building the much-needed collaborative bridges between silos,” says Dr. Marshall Summar, Director of Clinical Research at the Rare Disease Institute of the Children’s National Medical Center, and Chairman of the National Organization for Rare Disorders (NORD).
February 22, 2022
February is Rare Disease Month—an important time when the rare disease community comes together to raise awareness and advocate as one for the approximately 350 million people impacted by rare diseases globally.
As the number of pediatric clinical trials show signs of improvement, how to best sustain and scale them comes into play. Dr. Harsha Rajasimha of Jeeva Informatics addresses the challenges in making radical improvements in pediatric CT operations.
Decentralized Clinical Trials Raise Concerns About Informed Consent
The growing use of decentralized clinical trials has raised serious concerns regarding the verification of patient comprehension and proper informed consent. The solution, says Dr. Harsha Rajasimha of Jeeva Informatics, is to leverage the full potential of digital technology.
IRBs Scrutinizing Remote Consent, Screening, and Participation in Study Protocols
“One is communication. Research staff & patients need to be able to communicate via video, audio, text, email, in multiple ways from wherever you are. The second part is using technology to educate patients before, during, and after they participate in a clinical trial. It’s a divine contract that happens between the doctor and the patient that needs to occur and if that must happen remotely, as it has during the pandemic in many trials for the very first time before that 99 percent of all informed consents were in person.”
Clinical Research Processes Struggle to Adapt Amidst Pandemic
Some bright spots are relieving this dark picture, notes Dr. Harsha Rajasimha, Founder and CEO of Jeeva Informatics. "One bright spot," he says, "has been the speed at which vaccines against COVID have been developed. The pandemic has intensified worldwide research collaboration and a reprioritization and rethinking of the process of how healthcare is delivered or received."
November 24, 2021
Utilizing Technology to Increase Diversity, Recruitment, and Retention for Important Life-Saving Clinical Trials
When implemented efficiently, decentralization can mean real-time data capture rather than monthly or quarterly verified data by traveling clinical research associates in-person. Choosing a bring your own device (BYOD) solution can further improve diversity and access from patients located anywhere with access to a browser-enabled mobile device and Internet access. A cloud-based Software as a Service (SaaS) solution can save significant time and costs of IT infrastructure and hardware.
Human-Centric eClinical Platforms Can Eliminate Inefficiencies Rooted in Traditional Clinical Trials
"Serious inefficiencies are hampering clinical trials of new drugs and treatments, prolonging the suffering of millions. Today’s platform technologies, says Dr. Harsha K Rajasimha of Jeeva Informatics Solutions Inc., enable more flexible trials that are faster, more efficient, and more cost-effective than traditional approaches."
Ricardo Hazell of EURweb.com interviews our CEO Dr. Harsha Rajasimha on the Dire Need to Diversify Clinical Trials
Ricardo Hazell of @EURweb.com sat down with our CEO Dr. Harsha Rajasimha to discuss his perspectives on the Dire Need to Diversify Clinical Trials. “There are clinical research projects or clinical trials which can help patients living with chronic or rare diseases anywhere in the world. But 80 percent of all clinical trial participants continue to be Caucasian, most of them male and middle-aged from an affluent background.” How can digital health and SaaS technology help address this challenge?
Education, Outreach Keys to Overcoming Distrust of Clinical Trials
Michael Causey, Editor-in-Chief, Association of Clinical Research Professionals, interviews Dr. Harsha Rajasimha, CEO of Jeeva Informatics. The clinical trial industry must proactively address a record of “historical errors and misbehavior” in its treatment of minority populations if it wants to rebuild trust and increase patient involvement, says Dr. Rajasimha.
Five Critical Mistakes for Disruptive Innovators to Avoid
Disruptors are defined by several characteristics. They see beyond the existing status quo and challenge it by visualizing improvement and the outcome of that solution. Innovators do not provoke anger for its own sake, but they are not afraid to upset the competition or even potential allies. They are pioneering that solution not only to help themselves but also fix an issue that has long been plaguing their industry. Here are five mistakes innovators make which are serious enough to doom their idea.
Global Disruption: Decentralizing Clinical Trials for Diversity, Faster Results
According to data from the FDA, African Americans are only 5% of individuals included in clinical trials, despite being more than 13% of the total U.S. population. There are currently no regulatory demands on patient diversity. This leaves all minorities underrepresented in clinical trials—from women to members of the LGBTQ+ community, to people living in rural or hard-to-reach geographies.
Clinical Trials Need More Diversity—This Tech Company is Trying to Change That
Studies have found that when people with diverse backgrounds are not adequately represented, treatments shown to be effective in trials may not be effective for all populations. This is why focusing on diversity in clinical trials is critical from this point forward.
Distrust, Fear Hamper COVID Vaccinations, Clinical Trial Diversity
The medical research community needs to plan and work toward earning the trust of diverse patients in both in-person and online settings. It cannot be assumed or taken for granted. To help overcome the lingering effects of these long-ago but well-remembered occurrences, says Dr. Harsha Rajasimha, founder and CEO of Jeeva Informatics Solutions Inc., it is necessary to address patients’ fears with real facts and real data. Prospective clinical trial participants need to understand as clearly as possible what they are consenting to, what the risks might be, and how the potential results will benefit mankind.
Healthcare Innovators to Change How Industry Communicates Telehealth
Companies that organize and conduct clinical drug trials are challenged to find and retain participants. Current statistics show that 85% of all clinical trials are delayed during patient recruitment, and 30% are terminated early due to failure to enlist enough patients. Even the small proportion of trials that manage enroll the required number experience an average 30% dropout rate. However, there are companies bringing fully scalable modular software-as-a-service platform to facilitate patient enrollment, engagement, and evidence generation in clinical trials on any browser-enabled mobile device, effectively bringing much of the trial processes to the participant.
Patient-Centric Approach to Clinical Trials Improves Outcomes for All Stakeholders
According to researchers at the MIT Sloan School of Management, the probability of FDA approval of an industry-sponsored drug entering Phase One of the clinical trial process is 13.8%. A major factor in a trial’s success or failure, notes Dr. Harsha Rajasimha, founder and CEO of Jeeva Informatics Solutions Inc., is the trial sponsor’s ability to recruit and retain patients.
Decentralized Clinical Trials Boost Enrollment, Increase Patient Diversity
As medical centers were forced to focus on COVID-related care, and optional travel was curtailed by the need for physical distancing, patients’ access to clinical trial sites was reduced by some 80%. In response, notes Dr. Harsha Rajasimha, founder and CEO of Jeeva Informatics, sponsors have moved rapidly to shift as much clinical trial activity as possible from centralized locations to the patients’ homes or nearby facilities such as pharmacies—with positive results. “Decentralization,” says Dr. Rajasimha, “has proven to be highly beneficial to sponsors and patients alike, and to significantly improve patient diversity, recruitment, and retention.”
August 25, 2021
Jeeva Joins the Amazon Web Services Partner Network (APN)
Jeeva was named a digital innovation finalist for advancing pediatric rare disease research in the Bear Pack contest
August 15, 2021
Customer Case Study Announcement
A large US research University has signed up with Jeeva to run a 5-year longitudinal cohort study with 2500 participants on the Jeeva software. The academic research team will be transitioning over to Jeeva eClinical cloud a as single integrated platform and will retire the 3 different tools they were previously using. Their evaluation and pilot ran for the last several months.
August 01, 2021
Jeeva Wins the IGNITE Grant by Prince William County in Virginia
Jeeva is pleased to announce its selection as a winner of the competitive Prince William County IGNITE grant in Virginia. Prince William County’s IGNITE grant offers cash to selected high-growth companies and tech catalyst organizations. The $50,000 non-dilutive grant help Jeeva further commercialize the Jeeva eClinical Cloud in the thriving Bioscience park in PWC, commonwealth of Virginia, and beyond.
August 17, 2021
Removing Logistical Burdens, Maximizing Technological Solutions Could Improve Diversity in Clinical Trials
How Jeeva’s Technology Can Make An Important Impact In Our Overall Wellness
Our founder and CEO Harsha K. Rajasimha sat down with Authority Magazine's Dave Philistin for an in-depth interview about his entrepreneurial journey and mission to improve health outcomes through eClinical technology.
New Technology to Help Increase Patient Diversity in Clinical Trials
Patient test groups for new drugs and treatments, notes Dr. Harsha Rajasimha of Jeeva Informatics, tend to be non-diverse. However, recently developed digital health technologies can help broaden participation while reducing the logistical burden on both patients and study teams.
Cancer Genetics is a global company whose state-of-the-art diagnostic technologies help determine what will work best for each individual cancer patient and light a path for biophamaceurtical companies working with immunotherapies.
Jeeva was positioned in the Everest Group's inaugural #PEAKmatrix on Decentralized Clinical Trial Products for 2021
Decentralized Clinical Trials (DCTs), in which clinical trial data is collected through sensors or remote monitoring devices carried by a patient without the need to visit a site, can deliver many benefits to pharmaceutical companies, including cost savings, better patient recruitment and retention, and improved data quality.
Virginia awards grants to Tysons tech businesses for commercial research projects
Tysons Corner, VA: Two technology companies in Tysons have each received $100,000 grants as part of a new state initiative intended to support projects that turn research into commercial products or services. Gov. Ralph Northam announced yesterday (Monday) that Virginia will award $3.4 million in grants to 34 small, technology-focused businesses for the inaugural round of the Commonwealth Commercialization Fund (CCF), which launched in 2020 to help advance promising technology through the development process.
Governor Northam Announces $3.4 Million to Advance Research Commercialization in Key Technology Sectors
RICHMOND—Governor Ralph Northam today announced that 34 small technology-focused businesses in Virginia will receive a total of $3.4 million in Commonwealth Commercialization Fund (CCF) grants to commercialize research in an array of sectors, including agricultural and environmental technologies, autonomous systems, clean energy, cybersecurity, data analytics, life sciences, and space and satellites. These awards mark the inaugural funding round for CCF, which was developed through the Virginia Innovation Partnership Authority (VIPA).
Kennesaw State University completes a pilot study on the Jeeva eClinical Cloud Platform
Jeeva announced the completion of a collaborative project with Kennesaw State University comparing the usability of Jeeva eClinical cloud with the REDCap software that has been in use for 5000 academic institutions worldwide. The results are pending peer-review for a journal publication anticipated in Fall 2021.
Patient Recruitment is the Elephant Slowing the Speed of Clinical Trials
Clinical trials are the regulatory mechanisms agencies like the Food and Drug Administration (FDA) use to evaluate and review evidence of safety and efficacy of investigational medicines in humans.
With the cost of discovery and development of one novel therapy exceeding $2.5 billion over a duration of 10-15 years, according to a 2018 PhRMA report, initiating, conducting, and successfully completing a clinical trial of any kind is one of the most complex endeavors.
World Virtual Clinical Trial Service Providers Market 2020-2025, by Type of Therapeutic Area, End-Users, Phase of Development and Key Geographies
Dublin, April 27, 2021 (GLOBE NEWSWIRE) -- The "Virtual Clinical Trial Service Providers Market by Type of Therapeutic Area, End-Users, Phase of Development (Phase I, Phase II, Phase III and Phase IV), and Key Geographies: Industry Trends and Global Forecasts, 2020-2050" report has been added to ResearchAndMarkets.com's offering.
Source: Research and MarketsRead full story
January 28, 2021
Jeeva Informatics Hosts Rare Disease Panel on Decentralized, Patient-Focused Clinical Trials
In recognition of Rare Disease Day 2021, Jeeva Informatics (Jeeva) brought together a panel of experts to discuss the importance of transforming the clinical trial process for rare diseases. The panel included Annie Kennedy, Chief of Policy and Advocacy, EveryLife Foundation for Rare Diseases; Thomas Lester, Former Executive Director, Audentes Therapeutics; Scott Schliebner, Senior Vice President, Scientific Affairs & Therapeutic Expertise, PRA Health Sciences; and Dr. Eric Sid, Program Director, National Center for Advancing Translational Science, Office of Rare Disease Research, (NCATS)/NIH.
January 08, 2021
Jeeva Founder and CEO to Present to Investors at the 39th Annual JP Morgan Healthcare Conference January 11-14, 2021
Jeeva AI-driven eClinical cloud accelerates #clinicalresearch at scale with remote touchless patient recruitment and patient retention.
Schedule an appointment with on the BIO one on one partnering portal or here: https://lnkd.in/gyQHab9.
We look forward to kicking off the year with #JPM2021.
December 16, 2020
Jeeva's perspective article published on the Patient Worthy portal
Avoid These 5 Real-World Data Pitfalls When Planning your Patient Registry, Natural History, or Other Clinical Study for a Rare Disease
1. Don’t toggle between multiple software to manage the study.
2. Don’t expect your clinical team to manually configure & execute the study.
3. Don’t confuse informed consent with collecting signatures (electronic or otherwise).
4. Don’t skip planning for travel restrictions that could halt in-person office visits.
5. Don’t limit your study participants to a specific mobile device manufacturer.
May 13, 2020
Jeeva to present at the KiwiTech's First Online Version of its Minority Founders Demo Day
KiwiTech, a tech startup accelerator that helps early to growth-stage startups in their product development drive traction and access capital, announced that it will host the 4th edition of its Minority Founders Demo Day on May 14, 2020, virtually for the first time.
April 08, 2020
KiwiTech and Jeeva Informatics Solutions Announce Strategic Partnership
Washington, DC: KiwiTech, LLC, an innovation platform that helps startups build viable products, drive traction, and raise capital, today announced a strategic partnership with Jeeva Informatics Solutions Inc, an AI-driven startup that builds patient-focused big data and digital health solutions for accelerating clinical research.
March 12, 2020
Speeding Up the Search for Cures – Jeeva Informatics Solutions
By any measure, Harsha Rajasimha, PhD, was a successful man. He had published journal articles and chapters in professional textbooks; he had received patents, honors, and awards for his work. But none of these accomplishments equipped him to help his baby, who died from Edwards Syndrome, a rare congenital disease.
Source: America's SBDC
This Startup is on a Mission to Decentralize Cell and Gene Therapy Clinical Trials
For the cell and gene therapy revolution to be fully realized, physicians, research scientists, biomanufacturing experts, advocacy groups, regulatory bodies like the Food & Drug Administration (FDA) and other key stakeholders have to “Think Different”, as Apple famously encouraged.
Jan. 29, 2020
Five Biotechs Poised to Advance Their Rare Disease Programs in 2020
The Biohealth Capital Region (BHCR) is at the leading edge of the rare disease market with companies like American Gene Technologies, REGENXBIO, Cerecor, Asklepion Pharmaceuticals, Lediant, and others advancing their pipelines towards rare disease treatments and cures. The region’s robust rare disease sector also includes a host of companies that support rare disease research and development like Jeeva Informatics, GeneDx, Aperiomics and HemoShear among others. In short, the portfolio of rare disease companies and growing support ecosystems make the BHCR a global hub for rare disease R&D.
Source: Steve Surdez, StoryCore contribution to BioBuzz.io
Jan. 08, 2020
CIT GAP Funds Invests in Jeeva to Decentralize and Improve Clinical Trial Operations
The Center for Innovative Technology (CIT) today announced that CIT GAP Funds has invested in Herndon, Va.-based Jeeva Informatics Solutions Inc. (Jeeva), a precision medicine data science company focused on significantly accelerating clinical trial operations by taking trials to patients’ homes. Using AI and digital health technologies, Jeeva fast tracks patient recruitment, improves adherence to trial protocols, and reduces patient burden and dropout rates, solving some of the pressing challenges in bringing innovative medicines to market effectively. Jeeva plans to use the GAP Funds investment to advance customer pilot projects and use cases for further validation.
Source: Press release
Sep 11-13, 2019
Recent Advances in Systems and Network Medicine: Meeting Report from the First International Conference in Systems and Network Medicine
The First International Conference in Systems and Network Medicine gathered together 200 global thought leaders, scientists, clinicians, academicians, industry and government experts, medical and graduate students, postdoctoral scholars, and policymakers. Held at Georgetown University Conference Center in Washington D.C. on September 11–13, 2019, the event featured a day of pre-conference lectures and hands-on bioinformatics computational workshops followed by two days of deep and diverse scientific talks, panel discussions with eminent thought leaders, and scientific poster presentations. Topics ranged from Systems and Network Medicine in Clinical Practice; the role of -omics technologies in Health Care; the role of Education and Ethics in Clinical Practice, Systems Thinking, and Rare Diseases; and the role of Artificial Intelligence in Medicine. The conference served as a unique nexus for interdisciplinary discovery and dialogue and fostered the formation of new insights and possibilities for health care systems advances.
April 30, 2019
Industry Leaders Outline Five Important Elements Impacting Rare Disease Drug Development
Leaders from AstraZeneca, American Gene Technologies, REGENXBIO, GeneDX, and Jeeva Informatics Solutions recently converged on the newly redesigned 704 Quince Orchard innovation space in Gaithersburg, Maryland for a panel discussion on drug development and rare disease.
September 12, 2018
Summer Internship Program in Precision Medicine Creates a Win-Win for Students and Local Company
Technologies such as cloud, bigdata, nosql databases, mobile apps, wearable sensors, and healthcare data interoperability are buzz words to many, but they are technologies that are propelling the healthcare-IT field forward into new frontiers. The possibilities these technologies bring can aide in patient engagement, data aggregation, integration and analytics for precision medicine. This is the cutting-edge space that Jeeva Informatics, a local company, operates in. It’s also a very attractive field for students who are eager to get work experience in the emerging technologies of the future.